{"transactions":[{"id":768060,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T20:30:11.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":24122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":54122,"source":{"system":"sec-edgar","filing":"0001193125-26-234568","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000119312526234568/ownership.xml","form_type":"4"}},{"id":1121421,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-05T20:55:05.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":4.95,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0000950170-25-082448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000095017025082448/ownership.xml","form_type":"4"}},{"id":1121420,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T20:55:05.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on June 3, 2025, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0000950170-25-082448","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000095017025082448/ownership.xml","form_type":"4"}},{"id":1502113,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-24T23:18:18.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":10.3,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0000950170-24-064813","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000095017024064813/ownership.xml","form_type":"4"}},{"id":1502112,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-24T23:18:18.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on May 23, 2024, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":19500,"source":{"system":"sec-edgar","filing":"0000950170-24-064813","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000095017024064813/ownership.xml","form_type":"4"}},{"id":1852423,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T20:00:32.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34085,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":110.2,"expiration_date":"2032-12-08","underlying":"Common Stock","underlying_shares":34085},"source":{"system":"sec-edgar","filing":"0000899243-23-015761","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000089924323015761/doc4.xml","form_type":"4"}},{"id":1852422,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T20:00:32.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":86582,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":29.56,"expiration_date":"2032-05-19","underlying":"Common Stock","underlying_shares":86582},"source":{"system":"sec-edgar","filing":"0000899243-23-015761","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000089924323015761/doc4.xml","form_type":"4"}},{"id":1852421,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T20:00:32.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":70371,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":36.32,"expiration_date":"2031-11-13","underlying":"Common Stock","underlying_shares":70371},"source":{"system":"sec-edgar","filing":"0000899243-23-015761","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000089924323015761/doc4.xml","form_type":"4"}},{"id":1852420,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T20:00:32.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":240000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":6.7,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0000899243-23-015761","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000089924323015761/doc4.xml","form_type":"4"}},{"id":1852419,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T20:00:32.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":0.5,"expiration_date":"2028-05-22","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-23-015761","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000089924323015761/doc4.xml","form_type":"4"}},{"id":1852418,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-06-16T20:00:32.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14000,"ownership":{"direct":false,"nature":"By Stenhouse Family Fund"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a Donor of the Stenhouse Family Fund."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-015761","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000089924323015761/doc4.xml","form_type":"4"}},{"id":1852417,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-06-16T20:00:32.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12754,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 9,811 restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,.. (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-015761","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000089924323015761/doc4.xml","form_type":"4"}},{"id":1870054,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-06-02T22:57:01.000Z","date":"2023-06-01","kind":"other","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Stenhouse Family Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer of shares from the Reporting Person to the Stenhouse Family Fund, a Charitable Gift Fund (the \"Stenhouse Family Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a Donor of the Stenhouse Family Fund."}],"balance_after":14000,"source":{"system":"sec-edgar","filing":"0001209191-23-034013","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000120919123034013/doc4.xml","form_type":"4"}},{"id":1870053,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-06-02T22:57:01.000Z","date":"2023-06-01","kind":"other","planned":false,"acquired":false,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer of shares from the Reporting Person to the Stenhouse Family Fund, a Charitable Gift Fund (the \"Stenhouse Family Fund\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes a total of 266 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":12708,"source":{"system":"sec-edgar","filing":"0001209191-23-034013","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000120919123034013/doc4.xml","form_type":"4"}},{"id":1874925,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-30T23:01:37.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing in service on the Board through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":11.72,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-033022","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000120919123033022/doc4.xml","form_type":"4"}},{"id":1874924,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-30T23:01:37.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on May 25, 2023, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":9000,"source":{"system":"sec-edgar","filing":"0001209191-23-033022","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000120919123033022/doc4.xml","form_type":"4"}},{"id":2088056,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-14T01:38:32.000Z","date":"2022-12-09","kind":"grant","acquired":true,"shares":34085,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option will vest on December 9, 2023, and 1/48th of the shares subject to the option will vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date."}],"balance_after":34085,"derivative":{"exercise_price":110.2,"expiration_date":"2032-12-08","underlying":"Common Stock","underlying_shares":34085},"source":{"system":"sec-edgar","filing":"0001209191-22-061090","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000120919122061090/doc4.xml","form_type":"4"}},{"id":2088055,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-12-14T01:38:32.000Z","date":"2022-12-09","kind":"grant","acquired":true,"shares":9811,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Award of restricted stock units (\"RSUs\") granted under the Issuer's 2021 Incentive Award Plan.  Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting.  The award will vest and settle with respect to twenty-five percent (25%) of the total number of RSUs on December 9, 2023, 2024, 2025 and 2026, subject to the Reporting Person's continued service with the Issuer through each vest date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes a total of 2,631 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":26442,"source":{"system":"sec-edgar","filing":"0001209191-22-061090","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000120919122061090/doc4.xml","form_type":"4"}},{"id":2253734,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T20:50:21.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":7.4,"expiration_date":"2032-05-24","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-22-032588","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000120919122032588/doc4.xml","form_type":"4"}},{"id":2261972,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-20T23:15:46.000Z","date":"2022-05-20","kind":"grant","acquired":true,"shares":86582,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the third anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":86582,"derivative":{"exercise_price":29.56,"exercise_date":"2025-05-20","expiration_date":"2032-05-19","underlying":"Common Stock","underlying_shares":86582},"source":{"system":"sec-edgar","filing":"0001209191-22-031169","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000120919122031169/doc4.xml","form_type":"4"}},{"id":2510778,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-17T02:10:56.000Z","date":"2021-11-14","kind":"grant","acquired":true,"shares":70371,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option will vest on November 14, 2022, and 1/48th of the shares subject to the option will vest monthly thereafter, subject to the Reporting Person's continued service with the Issuer through each vest date."}],"balance_after":70371,"derivative":{"exercise_price":36.32,"expiration_date":"2031-11-13","underlying":"Common Stock","underlying_shares":70371},"source":{"system":"sec-edgar","filing":"0001209191-21-064936","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000120919121064936/doc4.xml","form_type":"4"}},{"id":2699062,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-24T21:44:51.000Z","date":"2021-05-21","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date."}],"balance_after":12500,"derivative":{"exercise_price":35.49,"expiration_date":"2031-05-20","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-21-035474","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000120919121035474/doc4.xml","form_type":"4"}},{"id":2786466,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-03-17T01:49:51.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":14000,"price":19,"value":266000.0,"ownership":{"direct":true},"balance_after":14000,"source":{"system":"sec-edgar","filing":"0001209191-21-021219","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000120919121021219/doc4.xml","form_type":"4"}},{"id":3181786,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Cologuard"}}],"security":"Restricted Stock Units","published_at":"2020-04-06T16:41:07.000Z","date":"2020-04-02","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents a restricted stock unit award granted on April 2, 2018 that partially vested on April 2, 2020. The restricted stock units vest in three equal annual installments beginning on April 2, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Represents a restricted stock unit award granted on April 2, 2018 that partially vested on April 2, 2020. The restricted stock units vest in three equal annual installments beginning on April 2, 2019."}],"balance_after":25000,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-20-023603","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919120023603/doc4.xml","form_type":"4"}},{"id":3181785,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Cologuard"}}],"security":"Common Stock","published_at":"2020-04-06T16:41:07.000Z","date":"2020-04-03","kind":"sale","acquired":false,"shares":11948,"price":56.69,"value":677332.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on April 2, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"In addition to the shares of Common Stock reported on this Form 4, which total 29,926 shares, Mr. Stenhouse also holds, in the aggregate, an additional 71,143 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock."}],"balance_after":29571,"source":{"system":"sec-edgar","filing":"0001209191-20-023603","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919120023603/doc4.xml","form_type":"4"}},{"id":3181784,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Cologuard"}}],"security":"Common Stock","published_at":"2020-04-06T16:41:07.000Z","date":"2020-04-02","kind":"exercise","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."}],"balance_after":41519,"source":{"system":"sec-edgar","filing":"0001209191-20-023603","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919120023603/doc4.xml","form_type":"4"}},{"id":3200863,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-19T20:34:57.000Z","date":"2020-03-17","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest with respect to one-third of the shares of common stock on March 17, 2021, and will vest with respect to the remaining shares in equal monthly installments over the following two years, subject to the reporting person's continuous service to the Company on the applicable vesting dates."}],"balance_after":20000,"derivative":{"exercise_price":29.84,"expiration_date":"2030-03-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-20-020283","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734751/000120919120020283/doc4.xml","form_type":"4"}},{"id":3241757,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Cologuard"}}],"security":"Restricted Stock Units","published_at":"2020-02-28T16:39:31.000Z","date":"2020-02-26","kind":"exercise","acquired":false,"shares":3262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents a restricted stock unit award granted on February 26, 2019 that partially vested on February 26, 2020. The restricted stock units vest in four equal annual installments beginning on February 26, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Represents a restricted stock unit award granted on February 26, 2019 that partially vested on February 26, 2020. The restricted stock units vest in four equal annual installments beginning on February 26, 2020."}],"balance_after":9789,"derivative":{"underlying":"Common Stock","underlying_shares":3262},"source":{"system":"sec-edgar","filing":"0001209191-20-013916","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919120013916/doc4.xml","form_type":"4"}},{"id":3241756,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Cologuard"}}],"security":"Common Stock","published_at":"2020-02-28T16:39:31.000Z","date":"2020-02-27","kind":"sale","acquired":false,"shares":1051,"price":80.27,"value":84363.77,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 26, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"In addition to the shares of Common Stock reported on this Form 4, which total 16,874 shares, Mr. Stenhouse also holds, in the aggregate, an additional 96,143 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock."}],"balance_after":16519,"source":{"system":"sec-edgar","filing":"0001209191-20-013916","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919120013916/doc4.xml","form_type":"4"}},{"id":3241755,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Cologuard"}}],"security":"Common Stock","published_at":"2020-02-28T16:39:31.000Z","date":"2020-02-26","kind":"exercise","acquired":true,"shares":3262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."}],"balance_after":17570,"source":{"system":"sec-edgar","filing":"0001209191-20-013916","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919120013916/doc4.xml","form_type":"4"}},{"id":3267279,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Cologuard"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-18T16:40:03.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":11445,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":11445,"derivative":{"exercise_price":98.18,"exercise_date":"2021-02-14","expiration_date":"2030-02-14","underlying":"Common Stock","underlying_shares":11445},"source":{"system":"sec-edgar","filing":"0001209191-20-010183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919120010183/doc4.xml","form_type":"4"}},{"id":3267278,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Cologuard"}}],"security":"Restricted Stock Units","published_at":"2020-02-18T16:40:03.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":14123,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units vest in four equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units vest in four equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":14123,"derivative":{"underlying":"Common Stock","underlying_shares":14123},"source":{"system":"sec-edgar","filing":"0001209191-20-010183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919120010183/doc4.xml","form_type":"4"}},{"id":3563000,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Cologuard"}}],"security":"Restricted Stock Units","published_at":"2019-04-04T16:24:56.000Z","date":"2019-04-02","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents a restricted stock unit award granted on April 2, 2018 that partially vested on April 2, 2019. The restricted stock units vest in three equal annual installments beginning on April 2, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Represents a restricted stock unit award granted on April 2, 2018 that partially vested on April 2, 2019. The restricted stock units vest in three equal annual installments beginning on April 2, 2019."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-19-023646","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919119023646/doc4.xml","form_type":"4"}},{"id":3562999,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Cologuard"}}],"security":"Common Stock","published_at":"2019-04-04T16:24:56.000Z","date":"2019-04-03","kind":"sale","acquired":false,"shares":11192,"price":92.539,"value":1035696.488,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on April 2, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"In addition to the shares of Common Stock reported on this Form 4, which total 14,471 shares, Mr. Stenhouse also holds, in the aggregate, an additional 73,837 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock."}],"balance_after":14308,"source":{"system":"sec-edgar","filing":"0001209191-19-023646","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919119023646/doc4.xml","form_type":"4"}},{"id":3562998,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Cologuard"}}],"security":"Common Stock","published_at":"2019-04-04T16:24:56.000Z","date":"2019-04-02","kind":"exercise","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."}],"balance_after":25500,"source":{"system":"sec-edgar","filing":"0001209191-19-023646","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919119023646/doc4.xml","form_type":"4"}},{"id":3626742,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Cologuard"}}],"security":"Restricted Stock Units","published_at":"2019-02-28T20:22:45.000Z","date":"2019-02-26","kind":"grant","acquired":true,"shares":13051,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These restricted stock units vest in four equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These restricted stock units vest in four equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":13051,"derivative":{"underlying":"Common Stock","underlying_shares":13051},"source":{"system":"sec-edgar","filing":"0001209191-19-014811","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919119014811/doc4.xml","form_type":"4"}},{"id":3626741,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Cologuard"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-28T20:22:45.000Z","date":"2019-02-26","kind":"grant","acquired":true,"shares":10786,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":10786,"derivative":{"exercise_price":92.62,"exercise_date":"2020-02-26","expiration_date":"2029-02-26","underlying":"Common Stock","underlying_shares":10786},"source":{"system":"sec-edgar","filing":"0001209191-19-014811","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919119014811/doc4.xml","form_type":"4"}},{"id":3668709,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Cologuard"}}],"security":"Common Stock","published_at":"2019-02-08T16:57:10.000Z","date":"2018-10-31","kind":"grant","acquired":true,"shares":500,"price":42.44,"value":21220.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock purchased through Employee Stock Purchase Plan."}],"balance_after":500,"source":{"system":"sec-edgar","filing":"0001209191-19-008602","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919119008602/doc5.xml","form_type":"5"}},{"id":3973711,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":45258,"kind":"person","name":"Stenhouse Mark","position":1,"cik":"0001734751","reported_name":"Stenhouse Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Cologuard"}}],"security":"Restricted Stock Units","published_at":"2018-04-03T16:58:22.000Z","date":"2018-04-02","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units vest in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units vest in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-18-023111","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919118023111/doc4.xml","form_type":"4"}}]}